Literature DB >> 15997443

Prevalence of family history of colorectal cancer in the general population.

R J Mitchell1, H Campbell, S M Farrington, D H Brewster, M E M Porteous, M G Dunlop.   

Abstract

BACKGROUND: Robust estimates of the prevalence of a family history of colorectal cancer in the general population are essential to inform planning of provision for colonoscopic surveillance and for clinical genetics services. However, there is a paucity of high-quality data.
METHODS: Computerized record linkage was used to assess systematically the family history of 160 cancer-free community subjects and thereby provide prevalence data that are independent of participant recall. The data set comprised 2664 first- and second-degree relatives of study subjects, with 148 068 years at risk.
RESULTS: Of people in the 30-70 years age range, 9.4 (95 per cent confidence interval (c.i.) 5.8 to 14.9) per cent had a first-degree relative affected by colorectal cancer, and 28.8 (95 per cent c.i. 22.3 to 36.2) per cent had an affected first- or second-degree relative. Between 0 and 3.1 per cent of study subjects merited colonic surveillance, depending on the stringency of the guidelines used.
CONCLUSION: An appreciable proportion of the general population has a relative affected by colorectal cancer, sufficient to merit screening under certain criteria. In the absence of good-quality evidence supporting colonoscopic surveillance in groups at moderate risk, these data directly inform the planning of services for people with a family history of colorectal cancer. However, the clinical risk and financial implications of screening should be taken into account. Copyright 2005 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15997443     DOI: 10.1002/bjs.5084

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

1.  Colorectal cancer screening in patients at moderately increased risk due to family history.

Authors:  Otto S Lin
Journal:  World J Gastrointest Oncol       Date:  2012-06-15

Review 2.  Evidenced-Based Screening Strategies for a Positive Family History.

Authors:  Jennifer M Kolb; Dennis J Ahnen; N Jewel Samadder
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-04-14

3.  Potential impact of family history-based screening guidelines on the detection of early-onset colorectal cancer.

Authors:  Samir Gupta; Balambal Bharti; Dennis J Ahnen; Daniel D Buchanan; Iona C Cheng; Michelle Cotterchio; Jane C Figueiredo; Steven J Gallinger; Robert W Haile; Mark A Jenkins; Noralane M Lindor; Finlay A Macrae; Loïc Le Marchand; Polly A Newcomb; Stephen N Thibodeau; Aung Ko Win; Maria Elena Martinez
Journal:  Cancer       Date:  2020-04-20       Impact factor: 6.860

4.  How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

Authors:  Janneke A Wilschut; Ewout W Steyerberg; Monique E van Leerdam; Iris Lansdorp-Vogelaar; J Dik F Habbema; Marjolein van Ballegooijen
Journal:  Cancer       Date:  2011-03-08       Impact factor: 6.860

5.  Screening patterns in patients with a family history of colorectal cancer often do not adhere to national guidelines.

Authors:  Otto S Lin; Michael Gluck; Matthew Nguyen; Johannes Koch; Richard A Kozarek
Journal:  Dig Dis Sci       Date:  2013-01-31       Impact factor: 3.199

Review 6.  Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state-of-the-science review.

Authors:  Jan T Lowery; Dennis J Ahnen; Paul C Schroy; Heather Hampel; Nancy Baxter; C Richard Boland; Randall W Burt; Lynn Butterly; Megan Doerr; Mary Doroshenk; W Gregory Feero; Nora Henrikson; Uri Ladabaum; David Lieberman; Elizabeth G McFarland; Susan K Peterson; Martha Raymond; N Jewel Samadder; Sapna Syngal; Thomas K Weber; Ann G Zauber; Robert Smith
Journal:  Cancer       Date:  2016-06-03       Impact factor: 6.860

7.  Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study.

Authors:  Sean P Cleary; Michelle Cotterchio; Mark A Jenkins; Hyeja Kim; Robert Bristow; Roger Green; Robert Haile; John L Hopper; Loic LeMarchand; Noralane Lindor; Patrick Parfrey; John Potter; Ban Younghusband; Steven Gallinger
Journal:  Gastroenterology       Date:  2008-12-27       Impact factor: 22.682

8.  Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals.

Authors:  Malcolm G Dunlop; Albert Tenesa; Susan M Farrington; Stephane Ballereau; David H Brewster; Thibaud Koessler; Paul Pharoah; Clemens Schafmayer; Jochen Hampe; Henry Völzke; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner; Susanna von Holst; Simone Picelli; Annika Lindblom; Mark A Jenkins; John L Hopper; Graham Casey; David Duggan; Polly A Newcomb; Anna Abulí; Xavier Bessa; Clara Ruiz-Ponte; Sergi Castellví-Bel; Iina Niittymäki; Sari Tuupanen; Auli Karhu; Lauri Aaltonen; Brent Zanke; Tom Hudson; Steven Gallinger; Ella Barclay; Lynn Martin; Maggie Gorman; Luis Carvajal-Carmona; Axel Walther; David Kerr; Steven Lubbe; Peter Broderick; Ian Chandler; Alan Pittman; Steven Penegar; Harry Campbell; Ian Tomlinson; Richard S Houlston
Journal:  Gut       Date:  2012-04-05       Impact factor: 23.059

9.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

10.  Screening patients with a family history of colorectal cancer.

Authors:  Robert H Fletcher; Rebecca Lobb; Mark R Bauer; James Alan Kemp; Richard C Palmer; Ken P Kleinman; Irina Miroshnik; Karen M Emmons
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.